Shire Archives

More News! 24 Aug 2018

Shire gets US market approval for rare inflammatory disease drug

The UK-US biotech giant’s drug Takhzyro has been approved by the FDA to prevent attacks of hereditary angioedema, a rare genetic disease that causes swelling around the body. Hereditary angioedema is a potentially life threatening genetic condition that people can inherit from either of their parents. Takhzyro (lanadelumab-flyo) is a first-in-class monoclonal antibody drug that […]

August 24, 2018 - 2 minutesmins - By Helen Albert

News and Trends 28 Feb 2018

Like Finding a Needle in a Haystack: How Are Biotechs Fighting Rare Diseases?

Rare diseases affect fewer than 1 in 2,000 people in Europe and less than 200,000 Americans at any given time. A lack of financial incentive has put pharma off but biotechs are keen to step in and develop treatments and cures. Over 6,000 rare diseases affect up to 30 million people in the EU alone, which highlights […]

February 28, 2018 - 8 minutesmins - By Alex Dale

News and Trends 20 Feb 2018

Microsoft Joins Shire to Diagnose Rare Diseases Much Faster

Microsoft has partnered with Shire and EURORDIS to accelerate the diagnosis of rare disease, a process that often takes years and takes a big toll on the health of millions. There are over 6,000 different rare diseases, most of them beginning in childhood. However, diagnosing them takes an average of 5 years, delaying the start […]

February 20, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

More News! 12 Sep 2017

Shire’s Treatment for Chronic Lung Disease in Premature Infants Fast Tracked by FDA

The FDA has fast tracked Shire’s candidate for chronic lung disease in extremely premature infants from Phase 2 of clinical development. The FDA has fast tracked Shire’s candidate, SHP607, for the treatment of chronic lung disease based on preclinical data, the results of Phase I and II studies so far, and a lack of treatments […]

September 12, 2017 - 1 minutemin - By Alex Dale

novimmune shire hemophilia antibody roche

News and Trends 18 Jul 2017

Shire In-Licenses Swiss Antibody for Hemophilia A to Compete with Roche

Shire has bought exclusive worldwide rights to develop and commercialize a bispecific antibody from Novimmune that could improve the treatment of hemophilia A. Novimmune is a biotech from Geneva that specializes in developing antibodies. Back in 2015, it struck a research collaboration with Baxalta, which has since been acquired Shire. The Irish pharma has now decided to […]

July 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Centogene Rare Disease Diagnostics Series A

News and Trends 13 Jun 2017

German Biotech Raises €25M to Fuel Diagnostics of Rare Diseases

Centogene has raised €25M in a Series A round to support the global expansion of its genome analysis platform, which is specialized in rare diseases. The German biotech Centogene is pioneering the development of genetic diagnostic tests to address the challenges of personalized medicine in order to match therapies more effectively to patients. Founded in 2005, the […]

June 13, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 5 Jan 2017

Shire sells its RNA platform to a US-based Biotech

Shire has sold its RNA therapy program to a smaller biotech that wants to accelerate the development of products from the platform. The Irish drug giant Shire is giving its MRT program, which includes two mRNA platforms and 12 employees, to US-based RaNA Therapeutics. In exchange, Shire will receive an undisclosed share of equity in the biotech as well […]

January 5, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 7 Nov 2016

Results from 45% of Clinical Trials are kept Secret

A new transparency study has identified Sanofi, Novartis and GSK as the companies that keep the most clinical trial results unreported. TrialsTracker is a tool developed at the University of Oxford that automatically rates transparency on clinical trials by checking if there are results available in clinicaltrials.gov and PubMed. The results: globally, 45% of data on […]

November 7, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 18 Oct 2016

Shire’s leading Pancreatic Cancer drug is Back with a Bang

Pancreatic cancer is one of the nastiest kinds and most difficult to treat; the EMA has granted marketing authorization to Onivyde in the fight against it. Pancreatic cancer is the fourth-leading cause of death in Europe, and it represents a dramatically underserved need. Metastatic adenocarcinoma is almost always fatal, as it cannot be removed surgically […]

October 18, 2016 - 2 minutesmins - By Evelyn Warner

jp morgan biotech san francisco california 2016

News and Trends 14 Jan 2016

The Biotech World is Buzzing: J.P. Morgan’s 2016 Phenomenon Kicks off this Week!

Imagine a conference where all the Biotech CEOs and investors of the World come together…all the major players in this Industry, under one roof. That’s basically what the J.P.Morgan Conference is about. Organized by the banking firm of the same name, it is the 34th edition this year. And with age, comes exclusivity: The J.P. […]

January 14, 2016 - 4 minutesmins - By Philip Hemme

embl microbiome janssen eligo enterome jj inra therapeutics crohns

News and Trends 7 Jan 2016

Collaboration is Key to Microbiomics: New Deal with The Janssen Human Microbiome Institute

The Janssen Human Microbiome Institute, the French National Institute for Agricultural Research (INRA) and Johnson & Johnson Innovation AND Takeda are signing up to collaborate with the Paris biotech Enterome to help accelerate Microbiomics research into Crohn’s Disease. The collaboration is based on initial findings by the INRA showing that some commensal (symbiotic) bacteria elicit […]

January 7, 2016 - 3 minutesmins - By Dani Bancroft

News and Trends 4 Nov 2015

Transformational deals that shaped the Biotech industry in 2015 #BIO-Europe 2015

The Biotech industry relies a lot on partnering and deals. And 2015 has already been an active year. This was the theme of the second keynote conference from BIO-Europe 2015. It gathered four high-level speakers: The roundtable started with a summary of each companies’ activity in deals. Everyone has been busy, but Celgene seemed to […]

November 4, 2015 - 3 minutesmins - By Philip Hemme

Resources

Categories

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Shire

Shire gets US market approval for rare inflammatory disease drug

Like Finding a Needle in a Haystack: How Are Biotechs Fighting Rare Diseases?

Microsoft Joins Shire to Diagnose Rare Diseases Much Faster

Shire’s Treatment for Chronic Lung Disease in Premature Infants Fast Tracked by FDA

Shire In-Licenses Swiss Antibody for Hemophilia A to Compete with Roche

German Biotech Raises €25M to Fuel Diagnostics of Rare Diseases

Shire sells its RNA platform to a US-based Biotech

Results from 45% of Clinical Trials are kept Secret

Shire’s leading Pancreatic Cancer drug is Back with a Bang

The Biotech World is Buzzing: J.P. Morgan’s 2016 Phenomenon Kicks off this Week!

Collaboration is Key to Microbiomics: New Deal with The Janssen Human Microbiome Institute

Transformational deals that shaped the Biotech industry in 2015 #BIO-Europe 2015

Subscribe to our newsletter to get the latest biotech news!

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!